Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-F3) - Biotin
| Code | Size | Price |
|---|
| LEI-LT7051-50ug | 50 ug | £377.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Virus
Antibody Isotype: Human IgG1
Antibody Clonality: Monoclonal
Antibody Clone: NP1-F3
Regulatory Status: RUO
Target Species:
- SARS-CoV-2
- Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Blue Ice
Storage:
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
SARS-CoV-2 Nucleocapsid (N) Protein
Long Description:
Coronavirus disease 2019 (COVID-19) is caused by the Coronaviridae family virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. SARS-CoV-2 has four structural proteins encoded by its single-stranded, positive-sense RNA genome: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. The N protein is a highly conserved 46 kDa protein that shares 90% homology with SARS-CoV3. The N protein has an N-terminal (NTD) and C-terminal domain (CTD), which bind to RNA and self-oligomerize, respectively4,5, forming a helical nucleocapsid structure within the viral envelope6. Other functions of the N protein included viral transcription, replication, and modulating cell signaling pathways7,8. The N protein is abundantly expressed during infection, and antibodies3,9 and memory T cells10,11 targeting the N protein have been identified in convalescent sera. Therefore, the N protein is a target in some vaccines and diagnostic assays12. The N protein also has therapeutic potential, as it evades RNAi-mediated antiviral responses13.
NCBI Gene:
43740575
Target:
SARS-CoV-2 Nucleocapsid (N)
References
1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020.
3. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
4. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
5. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
6. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
7. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
8. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
10. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.
Related Products
| Product Name | Product Code | Supplier | Anti-SARS-CoV-2 Spike RBD (Clone: 2165) | LEI-LT1900 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-SARS-CoV-2 Spike NTD (Clone 2146) | LEI-LT2000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2838) | LEI-LT3000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2381) | LEI-LT4000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike RBD (Clone: 2355) | LEI-LT5000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-SARS-CoV-2 Spike NTD (Clone 2215) | LEI-LT6000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant SARS-CoV-2, Nucleocapsid (N) Protein | LEI-S854 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||